Conduit Pharmaceuticals Inc.
CDT
$0.6201
-$0.16-20.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 98.85% | 439.07% | 136.88% | 86.60% | 35.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.91% | 1,158.37% | 138.78% | 95.05% | 41.22% |
| Operating Income | -96.91% | -1,158.37% | -138.78% | -95.05% | -41.22% |
| Income Before Tax | -1,082.04% | -346.13% | -155.60% | -112.44% | 107.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,082.04% | -346.13% | -155.60% | -112.44% | 107.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,082.04% | -346.13% | -155.60% | -112.44% | 107.98% |
| EBIT | -96.91% | -1,158.37% | -138.78% | -95.05% | -41.22% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -742.56% | -284.73% | -123.68% | -85.96% | 105.76% |
| Normalized Basic EPS | -999.86% | -262.05% | -123.68% | -85.96% | 105.66% |
| EPS Diluted | 41.25% | -1,224.40% | -123.68% | -79.82% | 37.02% |
| Normalized Diluted EPS | -1,022.81% | -263.84% | -127.83% | -87.09% | 105.52% |
| Average Basic Shares Outstanding | 52.84% | 33.25% | 14.27% | 14.23% | 38.54% |
| Average Diluted Shares Outstanding | 48.99% | 31.80% | 12.18% | 13.55% | 42.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |